26 Jul Coave Therapeutics
Rodolphe Clerval, CEO
Oct. 12 | 1:30pm | Oxford Biomedica Ballroom
Coave Therapeutics develops gene therapy products in CNS and ophthalmology based on a unique AAV-ligand platform for improved delivery of payloads in deep structures of the brain and the eye. We have three preclinical CNS programs with a focus on enhancing the autophagy-lysosomal pathway in neurodegenerative diseases. Our legacy program, CTx-PDE6b for PDE6b mutated inherited retinal dystrophies, has achieved enrollment of a Phase I/II study with read-out expected in the next two years.